Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 17/20 | 0.52 |
| ▸ | CCND1 | P24385 | 17/20 | 0.52 |
| ▸ | CCND3 | P30281 | 14/20 | 0.52 |
| ▸ | CCND2 | P30279 | 12/20 | 0.52 |
| ▸ | CDK2 | P24941 | 6/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.52 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.52 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.52 |
| ▸ | CDK1 | P06493 | 3/20 | 0.52 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.52 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.52 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.52 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.52 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.52 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.52 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13202803 | 0.97 | CDK4 (0.54) | CDK4CCND1CCND3CCND2CDK2 | |
| SCHEMBL29611418 | 0.97 | CDK4 (0.54) | CDK4CCND1CCND3CCND2CDK2 | |
| SCHEMBL22553630 | 0.89 | CDK4 (0.52) | CDK4CCND1CCND3CCND2CDK2 | |
| SCHEMBL22553631 | 0.89 | CDK4 (0.52) | CDK4CCND1CCND3CCND2CDK2 | |
| SCHEMBL17545217 | 0.88 | CDK4 (0.47) | CDK4CCND1CCND3CCND2CDK2 | |
| SCHEMBL22553501 | 0.88 | CCND1 (0.42) | CDK4CCND1CCND3CCND2CDK2 | |
| SCHEMBL28403699 | 0.85 | CDK4 (0.56) | CDK4CCND1CCND3CCND2CDK2 | |
| SCHEMBL22553614 | 0.84 | CDK4 (0.45) | CDK4CCND1CCND3CCND2CDK2 | |
| SCHEMBL16248282 | 0.82 | CDK4 (0.54) | CDK4CCND1CCND3CCND2CDK2 | |
| SCHEMBL20448740 | 0.82 | CDK4 (0.54) | CDK4CCND1CCND3CCND2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3956031-A1 | ANTI-PROLIFERATIVE AGENTS FOR TREATING PAH | Pfizer Inc. (US) | 2022-02-23 | — | — | EP | disclosed |
| CN-114007697-A | Antiproliferative agents for the treatment of PAH | 辉瑞公司 | 2022-02-01 | — | — | CN | disclosed |
| US-11203594-B2 | Anti-proliferative agents for treating PAH | PFIZER INC. (US) | 2021-12-21 | — | — | US | disclosed |
| WO-2020212865-A1 | ANTI-PROLIFERATIVE AGENTS FOR TREATING PAH | PFIZER INC. (US) | 2020-10-22 | — | — | WO | disclosed |
| US-20200331909-A1 | ANTI-PROLIFERATIVE AGENTS FOR TREATING PAH | PFIZER INC. (US) | 2020-10-22 | — | — | US | disclosed |
| WO-2020212865-A1 | ANTI-PROLIFERATIVE AGENTS FOR TREATING PAH | PFIZER INC. (US) | 2020-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11203594-B2 | Anti-proliferative agents for treating PAH | EDNRB, EDNRA, PAH | CDK4 219/4885CCND1 108/4885CCND3 143/4885 |
| US-20200331909-A1 | ANTI-PROLIFERATIVE AGENTS FOR TREATING PAH | EDNRB, EDNRA, PAH | CDK4 219/4885CCND1 108/4885CCND3 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.